TD Cowen Reiterates Buy Rating on ABCL After AbCellera Biologics Dosed First Participants of ABCL575

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 11, TD Cowen reiterated its Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL), without giving a price target.

TD Cowen analyst Brendan Smith sees the company’s focus on expanding its internal pipeline and strengthening its partnerships through the Biosecure program as catalysts for AbCellera. On August 27, AbCellera reported that it dosed the first participants in its Phase 1 clinical trial of ABCL575, a next-generation antibody treatment for moderate-to-severeatopic dermatitis (AD). The therapy will potentially help in the treatment of other inflammatory and autoimmune conditions. The company expects the data from this study in mid-2026.

TD Cowen Reiterates Buy Rating on ABCL After AbCellera Biologics Dosed First Participants of ABCL575

Smith believes that the company’s liquidity position is good, as AbCellera is well-equipped in terms of financial resources and operational capacity. This positions the company to invest in strategic initiatives such as ABCL575 and navigate market conditions.

AbCellera Biologics Inc. (NASDAQ:ABCL) focuses on discovering and developing antibody-based treatments for indications with unmet medical needs in the U.S.

While we acknowledge the potential of ABCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABCL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.